Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Expert Insights

Oleg Gluz, MD, West German Study Group
Videos
Response to Short Preoperative Endocrine Therapy Among Patients With HR-Positive, HER2-Negative Breast Cancer
12/08/2023

Featuring Oleg Gluz, MD

Featuring Oleg Gluz, MD
Oleg Gluz, MD, shares results from the screening cohort of the phase 3 ADAPTcycle trial.
Oleg Gluz, MD, shares results from the screening cohort of the phase 3 ADAPTcycle trial.
Oleg Gluz, MD, shares results...
12/08/2023
Oncology
John Robertson, MD chB BSc, MD, FRCS
Conference Coverage
Optimal Camizestrant Dose for Patients With ER-Positive, HER2-Negative Primary Breast Cancer
12/08/2023

Featuring John Robertson, MD chB BSc, MD, FRCS

Featuring John Robertson, MD chB BSc,...
John Robertson MB chB BSc, MD, FRCS, shared results from the SERENA-3 trial, investigating the effect multiple doses of camizestrant at different treatment durations has on ER, ki-67, and PgR expression.
John Robertson MB chB BSc, MD, FRCS, shared results from the SERENA-3 trial, investigating the effect multiple doses of camizestrant at different treatment durations has on ER, ki-67, and PgR expression.
John Robertson MB chB BSc, MD,...
12/08/2023
Oncology
Peter Schmid, MD, PhD, Barts Cancer Center
Videos
Addition of Pembrolizumab to Neoadjuvant Chemotherapy Plus Adjuvant Pembrolizumab Improved EFS Among Patients with Early-Stage Triple-Negative Breast Cancer
12/08/2023

Featuring Peter Schmid, MD, PhD

Featuring Peter Schmid, MD, PhD ...
Peter Schmid, MD, PhD, presents updated results from the KEYNOTE-522 study, describing the benefit of adding pembrolizumab to neoadjuvant chemotherapy with adjuvant pembrolizumab in early-stage triple-negative breast cancer.
Peter Schmid, MD, PhD, presents updated results from the KEYNOTE-522 study, describing the benefit of adding pembrolizumab to neoadjuvant chemotherapy with adjuvant pembrolizumab in early-stage triple-negative breast cancer.
Peter Schmid, MD, PhD, presents...
12/08/2023
Oncology
Michail Ignatiadis, MD, PhD, Jules Bordet Institute
Videos
No Benefit From Addition of Atezolizumab to Adjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer
12/07/2023

Featuring Michail Ignatiadis, MD, PhD

Featuring Michail Ignatiadis, MD, PhD...
Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.
Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.
Michail Ignatiadis, MD, PhD,...
12/07/2023
Oncology
Bradley Monk, MD
Conference Coverage
Front-Line Treatment Options for Ovarian Cancer
12/07/2023

Featuring Bradley Monk, MD

Featuring Bradley Monk, MD
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates...
12/07/2023
Oncology
Aditya Bardia, MD, MPH
Conference Coverage
Datopotamab Deruxtecan for Patients With Previously Treated, Inoperable, or Metastatic HR-Positive, HER2-Negative Breast Cancer
12/07/2023

Featuring Aditya Bardia, MD, MPH

Featuring Aditya Bardia, MD, MPH ...
Aditya Bardia, MD, MPH, discussed results from the TROPION-Breast01 trial comparing datopotamab deruxtecan, a TROP-2 directed antibody drug conjugate, with standard chemotherapy in endocrine-resistant metastatic breast cancer.
Aditya Bardia, MD, MPH, discussed results from the TROPION-Breast01 trial comparing datopotamab deruxtecan, a TROP-2 directed antibody drug conjugate, with standard chemotherapy in endocrine-resistant metastatic breast cancer.
Aditya Bardia, MD, MPH,...
12/07/2023
Oncology
Antonio Llombart-Cussac MD, PhD
Conference Coverage
Palbociclib Plus Fulvestrant or Letrozole for HR-Positive, HER2-Negative Advanced Breast Cancer
12/07/2023

Featuring Antonio Llombart-Cussac MD, PhD

Featuring Antonio Llombart-Cussac MD,...
Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.
Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.
Antonio Llombart-Cussac MD, PhD,...
12/07/2023
Oncology
Hongnan Mo, MD
Conference Coverage
Efficacy, Safety of Toripalimab Plus Metronomic Chemotherapy for HER2-Negative Metastatic Breast Cancer
12/07/2023

Featuring Hongnan Mo, MD

Featuring Hongnan Mo, MD
Hongnan Mo, MD, discussed results from a phase 2 study comparing metronomic chemotherapy plus PD-1 blockade to combined conventional chemotherapy plus immune checkpoint blockade.
Hongnan Mo, MD, discussed results from a phase 2 study comparing metronomic chemotherapy plus PD-1 blockade to combined conventional chemotherapy plus immune checkpoint blockade.
Hongnan Mo, MD, discussed...
12/07/2023
Oncology
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
Selecting CDK4/6 Inhibitors for Patients With ER-Positive Early Breast Cancer
12/07/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...
Cynthia Ma, MD, leads part 2 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting CDK4/6 inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 2 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting CDK4/6 inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 2 of...
12/07/2023
Oncology
Sara Hurvitz, MD, Fred Hutchinson Cancer Center
Videos
Tucatinib Plus Trastuzumab Emtansine Improved Progression-Free Survival Among Patients With HER2-Positive Metastatic Breast Cancer
12/06/2023

Featuring Sara Hurvitz, MD

Featuring Sara Hurvitz, MD
Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.
Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.
Sara Hurvitz, MD, shares results...
12/06/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement